117846-66-9

Upstream product

• 4897-84-1 Methyl 4-bromobutyrate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 1178874-32-2 methyl 4-(4-bromomethylphenoxy)butyrate 

Relevant academic research and scientific papers

A Promising Material for Non-linear Optics: Observation of Second Harmonic Generation from 4--4'-nitrostilbene-coated Substrates

Glass coated with a nitro amino stilbene carboxylic acid using the Langmuir-Blodgett technique gave a non-centrosymmetric material second harmonic generation, 1.06 to 0.53 μm.

Metalloporphyrin-Based Porous Coordination Polymers: Synthesis, Served as Heterogenous Catalysts and Dye Scavengers

Abstract: Six metalloporphyrin-based porous coordination polymers, MnII(TCP)-MnII(CP1), FeIII(TCP)-FeIII(CP2), CoII(TCP)-CoII(CP3), NiII(TCP)-NiII(CP4), CuII/sup

Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections

Invasive fungal infections remain a challenge due to lack of effective antifungal agents and serious drug resistance. Discovery of antifungal agents with novel antifungal mechanism is important and urgent. Previously, we designed the first CYP51/HDAC dual

Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by a progressive-fibrosing phenotype. IPF has been associated with aberrant HDAC activities confirmed by our immunohistochemistry studies on HDAC6 overexpression in IPF lung tissues. We herein developed a series of novelhHDAC6 inhibitors, having low inhibitory potency overhHDAC1 andhHDAC8, as potential pharmacological tools for IPF treatment. Their inhibitory potency was combined with lowin vitroandin vivotoxicity. Structural analysis of 6h and structure-activity relationship studies contributed to the optimization of the binding mode of the new molecules. The best-performing analogues were tested for their efficacy in inhibiting fibrotic sphere formation and cell viability, proving their capability in reverting the IPF phenotype. The efficacy of analogue 6h was also determined in a validated human lung model of TGF-β1-dependent fibrogenesis. The results highlighted in this manuscript may pave the way for the identification of first-in-class molecules for the treatment of IPF.

Triazole CYP51-HDAC double-target antifungal compound as well as preparation method and application thereof

The invention discloses a triazole CYP51-HDAC double-target antifungal compound, which has a structural general formula disclosed in the invention, wherein R is selected from one of the structures disclosed in the invention. According to the triazole CYP5

Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them

Disclosed are processes for the preparation of compounds of formula I and compositions that comprise said compounds of formula I. Also disclosed are processes for the preparation of compounds of formula III and compositions that comprise said compounds of formula III.

ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses. (I)

Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1

We have synthesized and evaluated a series of diketopiperazine-based inhibitors of PAI-1. These studies resulted in the identification of 34 which inhibited PAI-1 in vitro with an IC50 = 0.2 μM. The synthesis and SAR of these compounds are desc